Filing identity and reporting period
Important identity discrepancy: The supplied filing is Aerovate Therapeutics, Inc.’s Form 10-Q for the quarter ended September 30, 2021—not a filing for Jade Biosciences, Inc. Verify the issuer before relying on this summary.
Aerovate is a clinical-stage biopharmaceutical company developing AV-101, an inhaled dry-powder formulation of imatinib for pulmonary arterial hypertension (PAH). It had no approved products or product-sales revenue.
Financial performance and position
Amounts below are in U.S. dollars; financial statement figures are in millions unless otherwise noted.
| Metric | Three months ended September 30 | Nine months ended September 30 |
|---|---|---|
| Research and development expense | 2021: $3.4; 2020: $2.0 | 2021: $9.9; 2020: $4.6 |
| General and administrative expense | 2021: $2.8; 2020: $0.3 | 2021: $4.8; 2020: $0.6 |
| Total operating expense | 2021: $6.2; 2020: $2.2 | 2021: $14.8; 2020: $5.2 |
| Net loss | 2021: $6.2; 2020: $2.3 | 2021: $14.7; 2020: $5.9 |
| Net loss per share, basic and diluted | 2021: $0.26 loss; 2020: $10.13 loss | 2021: $1.80 loss; 2020: $25.20 loss |
No revenue or meaningful operating margin was reported; profitability and revenue margins are not applicable to this development-stage business.
- Cash and liquidity: Cash and cash equivalents were $180.9 million at September 30, 2021, versus $4.6 million at December 31, 2020. Current assets were $183.1 million and current liabilities were $3.8 million.
- Cash flow, nine months: $14.3 million used in operations, $0.1 million used in investing, and $190.7 million provided by financing; cash increased by $176.3 million.
- Debt and obligations: No long-term debt was reported. Total liabilities were $4.3 million, including operating lease liabilities; the Waltham lease liability was $0.6 million.
- Equity financing: The July 2021 IPO generated approximately $126.9 million in net proceeds. The company also received $63.5 million net from Series A preferred-stock sales during the nine months. Preferred shares converted to common stock at the IPO.
Material changes versus the prior comparable period
Third-quarter net loss increased by $3.9 million year over year; nine-month net loss increased by $8.8 million. R&D increases reflected higher clinical and manufacturing costs. G&A rose substantially, including payroll, stock-based compensation, professional services, and insurance. The reported per-share loss is not directly comparable without considering the large increase in weighted-average shares following the IPO and preferred-stock conversion.
Financing proceeds lifted cash from $4.6 million at year-end 2020 to $180.9 million at quarter-end. The company also began leasing its Waltham headquarters in September 2021 and reported a second, short-term office lease signed after quarter-end.
Outlook, risks, and notable items
- Management expected existing cash to fund planned operations into the second half of 2025, while cautioning that actual cash use could be higher or timing could change. The financial statements also state cash was expected to cover obligations for at least 12 months from the report’s filing date.
- The company planned to initiate a global Phase 2b/3 AV-101 trial in PAH in the second half of 2021. The Phase 2b portion was expected to target 200 patients, with topline data anticipated in mid-2023. These are forward-looking plans, not reported trial outcomes.
- AV-101 was the company’s only development candidate. Phase 1 testing was in healthy volunteers, not PAH patients; prior oral-imatinib results may not predict AV-101’s efficacy or tolerability. Oral imatinib’s PAH trial showed efficacy on some measures but significant adverse events and no difference in time to clinical worsening.
- Material execution risks include clinical-trial enrollment and results, regulatory approval and the 505(b)(2) pathway, the drug-device combination review, reliance on third-party manufacturers and CROs, and the absence of issued patents for AV-101. COVID-19 could disrupt trials, enrollment, suppliers, and timelines.
- Management reported effective disclosure controls as of September 30, 2021, and no material quarter changes in internal control over financial reporting. The filing disclosed no material legal proceedings and no off-balance-sheet arrangements.
Most important facts for investors to verify
- Confirm the issuer: the source filing names Aerovate Therapeutics, not Jade Biosciences.
- Check subsequent disclosures for whether and when the Phase 2b/3 trial began, enrollment progress, safety findings, and updates to expected data timing.
- Assess actual quarterly cash burn and whether the stated second-half-2025 runway remains supportable under current development plans.
- Review updates on manufacturing and inhaler supply, regulatory feedback, and patent applications or issued patent protection.
- Consider the dilution and share-count effects of the IPO, preferred-stock conversion, and outstanding stock options.